Phase I study of spirogermanium given daily

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Spirogermanium, an azaspirane compound, demonstrated antitumor activity in prior limited trials.
• Previous studies utilized weekly intravenous injections of spirogermanium.
• Lack of myelosuppression prompted further investigation into alternative dosing schedules.

Purpose of the Study:

• To investigate the clinical effects of spirogermanium administered on various schedules.
• To determine the maximum tolerated doses for different administration routes and durations.
• To evaluate the efficacy and toxicity profile of spirogermanium in patients with advanced metastatic tumors.

Main Methods:

• 52 patients with refractory advanced metastatic tumors received spirogermanium.
• Three schedules were evaluated: daily IV infusion (5 days/wk), 24-hr continuous infusion (5 days/wk), and daily continuous infusion.
• Dose escalation and toxicity assessments were performed for each schedule.

Main Results:

• Partial responses and minor tumor regressions were observed in 6 patients, all with lymphoma.
• Neurologic toxicity was dose-limiting; other side effects included anorexia, nausea, vomiting, and potential lung toxicity.
• Continuous infusion allowed for twofold higher dose levels compared to standard IV schedules.

Conclusions:

• Spirogermanium can be administered daily via multiple schedules, with optimal dosage dependent on infusion time and duration.
• Continuous infusion strategies may enhance spirogermanium delivery and potential therapeutic benefit.
• Further research is warranted to optimize spirogermanium dosing for cancer treatment.